Total Payments
$67,030
2024 Payments
$759.78
Companies
36
Transactions
474
Medicare Patients
27,857
Medicare Billing
$3.3M
Payment Breakdown by Category
Other$49,246 (73.5%)
Food & Beverage$7,271 (10.8%)
Consulting$5,450 (8.1%)
Travel$5,063 (7.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $49,246 | 23 | 73.5% |
| Food and Beverage | $7,271 | 436 | 10.8% |
| Consulting Fee | $5,450 | 5 | 8.1% |
| Travel and Lodging | $5,063 | 10 | 7.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $35,585 | 172 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $13,217 | 22 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $8,902 | 26 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $2,792 | 13 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $2,605 | 5 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $1,003 | 64 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $630.29 | 45 | $0 (2024) |
| Merck Sharp & Dohme LLC | $313.68 | 19 | $0 (2024) |
| Amgen Inc. | $227.42 | 15 | $0 (2024) |
| ABIOMED | $213.25 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $759.78 | 44 | Novartis Pharmaceuticals Corporation ($227.10) |
| 2023 | $609.35 | 37 | PFIZER INC. ($136.14) |
| 2022 | $1,045 | 48 | AstraZeneca Pharmaceuticals LP ($270.98) |
| 2021 | $5,534 | 54 | AstraZeneca Pharmaceuticals LP ($4,816) |
| 2020 | $4,079 | 37 | AstraZeneca Pharmaceuticals LP ($3,678) |
| 2019 | $16,877 | 72 | PFIZER INC. ($12,240) |
| 2018 | $16,217 | 97 | PFIZER INC. ($10,825) |
| 2017 | $21,909 | 85 | PFIZER INC. ($11,826) |
All Payment Transactions
474 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.64 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $13.75 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $10.26 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/07/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $43.31 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/07/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: DIABETES | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.05 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/15/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $12.03 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/01/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $13.75 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/26/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $16.81 | General |
| Category: Cardiovascular | ||||||
| 09/25/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/23/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: Genetic Disease | ||||||
| 08/13/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $25.24 | General |
| Category: Genetic Disease | ||||||
| 08/06/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: Not Applicable | ||||||
| 07/30/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/23/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $17.42 | General |
| 07/17/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.19 | General |
| Category: Cardiology | ||||||
| 07/11/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $37.23 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/25/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/13/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 06/12/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $28.54 | General |
| Category: Genetic Disease | ||||||
| 06/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $11.99 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/28/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $12.62 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 5,989 | 7,097 | $2.6M | $697,427 |
| 2022 | 37 | 6,074 | 7,551 | $2.8M | $788,300 |
| 2021 | 37 | 7,183 | 8,960 | $2.9M | $803,178 |
| 2020 | 36 | 8,611 | 10,810 | $3.7M | $1.0M |
Total Patients
27,857
Total Services
34,418
Medicare Billing
$3.3M
Procedure Codes
141
All Medicare Procedures & Services
141 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78492 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress | Office | 2023 | 187 | 187 | $748,000 | $201,514 | 26.9% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2023 | 195 | 199 | $139,020 | $106,025 | 76.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 774 | 1,016 | $182,535 | $90,532 | 49.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 658 | 669 | $633,297 | $73,084 | 11.5% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 454 | 457 | $235,940 | $58,955 | 25.0% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 226 | 908 | $113,500 | $40,173 | 35.4% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 75 | 76 | $110,200 | $23,307 | 21.1% |
| 78434 | Nuclear medicine study of heart muscle blood flow by pet | Office | 2023 | 180 | 180 | $53,357 | $22,623 | 42.4% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 19 | 21 | $31,500 | $12,016 | 38.1% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 248 | 250 | $61,069 | $11,830 | 19.4% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 593 | 618 | $46,350 | $10,094 | 21.8% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 618 | 646 | $32,300 | $8,413 | 26.0% |
| 93241 | Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 36 | 37 | $11,760 | $6,538 | 55.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 587 | 651 | $37,107 | $6,523 | 17.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 602 | 630 | $56,700 | $6,481 | 11.4% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 75 | 78 | $43,890 | $4,378 | 10.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 58 | 59 | $7,135 | $3,772 | 52.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $5,290 | $2,488 | 47.0% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 31 | 31 | $8,680 | $1,465 | 16.9% |
| 82306 | Vitamin d-3 level | Office | 2023 | 47 | 47 | $10,575 | $1,363 | 12.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 18 | 18 | $2,700 | $1,344 | 49.8% |
| 93308 | Ultrasound of heart, follow-up | Office | 2023 | 16 | 16 | $4,530 | $1,019 | 22.5% |
| 93017 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) | Office | 2023 | 39 | 39 | $5,460 | $808.28 | 14.8% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 75 | 75 | $3,150 | $781.63 | 24.8% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 40 | 40 | $2,540 | $607.62 | 23.9% |
About Dr. Bart Denys, MD
Dr. Bart Denys, MD is a Cardiovascular Disease healthcare provider based in Thibodaux, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/06/2005. The National Provider Identifier (NPI) number assigned to this provider is 1659378685.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bart Denys, MD has received a total of $67,030 in payments from pharmaceutical and medical device companies, with $759.78 received in 2024. These payments were reported across 474 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($49,246).
As a Medicare-enrolled provider, Denys has provided services to 27,857 Medicare beneficiaries, totaling 34,418 services with total Medicare billing of $3.3M. Data is available for 4 years (2020–2023), covering 141 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Interventional Cardiology
- Location Thibodaux, LA
- Active Since 07/06/2005
- Last Updated 12/16/2019
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1659378685
Products in Payments
- ELIQUIS (Drug) $42,771
- FARXIGA (Drug) $8,765
- CHANTIX (Drug) $5,835
- PRALUENT (Drug) $2,692
- PRALUENT ALIROCUMAB INJECTION (Biological) $2,569
- XARELTO (Drug) $1,028
- ENTRESTO (Drug) $445.74
- VERQUVO (Drug) $313.68
- Impella (Device) $213.25
- ONPATTRO (Drug) $187.92
- LEQVIO (Drug) $184.55
- LifeVest (Device) $175.66
- Repatha (Biological) $154.05
- Livalo (Drug) $123.44
- BRILINTA (Drug) $122.09
- JARDIANCE (Drug) $111.33
- VYNDAQEL (Drug) $86.19
- RF Conductr (Device) $82.85
- ZONTIVITY (Drug) $81.78
- Corlanor (Drug) $73.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Thibodaux
Mohammed Rais, Md, MD
Cardiovascular Disease — Payments: $15,122
Cardiovascular Disease $15,122
Sandeep Patel, Md, MD
Cardiovascular Disease — Payments: $7,757
Cardiovascular Disease $7,757
Alvin Timothy, M.d, M.D
Cardiovascular Disease — Payments: $3,406
Cardiovascular Disease $3,406
Paritosh Kafle, Md, MD
Cardiovascular Disease — Payments: $1,207
Cardiovascular Disease $1,207
Dr. Carolyn Hebert, M.d, M.D
Cardiovascular Disease
Cardiovascular Disease